2022 Annual General Meeting
Further to the press release of June 1, 2022 giving notice that the Golar LNG Limited 2022 Annual General Meeting will be held on August 10, 2022, a copy of the Notice of Annual General Meeting and associated information including the Company’s Annual Report on Form 20-F can be found on our website at http://www.golarlng.com and in the attachments below.
Golar LNG Limited
June 30, 2022
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
AttachmentsTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Hoylu AB: Continued SaaS growth in July15.8.2022 08:30:00 CEST | Press release
Stockholm, Sweden, August 15, 2022 – Hoylu, a leader in visual collaboration solutions for distributed teams, today announced Annual Recurring Revenue (“ARR”) as of the end of July 2022. ARR, including long term mobile contracts, reached MSEK 48.5 as of the end of July 2022, up from MSEK 46.2 as of the end of June 2022. The report for July 2022 is attached to this press release and is available on Hoylu's web site: (https://www.hoylu.com/investor-relations/financial-reports/). For more information, please contact: Truls Baklid, CEO, +47 924 38 900 Email: email@example.com Karl Wiersholm, CFO, +1 425 829 2316 Email: firstname.lastname@example.org About Hoylu Hoylu's Adaptive Workspace opens up a new way for teams to plan, build and engage --so they get the impact they want no matter the industry, department or time. Whatever your management or planning style, Hoylu fits the way you structure your team and integrates all the productivity tools you're already using. So, you easily plan and complete any project
Expereo acquires Breeze Networks, further enhancing its SD-WAN/SASE practice and presence in the UK market15.8.2022 08:00:00 CEST | Press release
AMSTERDAM, Aug. 15, 2022 (GLOBE NEWSWIRE) -- The world’s leading provider of managed network solutions, Expereo, has announced the acquisition of Breeze Networks, a managed service provider of SD-WAN/SASE technologies. The acquisition fuels Expereo’s growth trajectory, further enhancing its SD-WAN/SASE practice, building on its expanding range of services to manage SD-WAN solutions at scale to partners and multinational enterprise customers across the globe. This latest acquisition solidifies Expereo’s ambition to complement its managed network solutions with world-class advisory practice providing guidance to organizations on their global transformation to software-defined and internet-based networking. With the full support of majority investor Vitruvian Partners and minority investor Apax Partners SAS, Expereo intends to continue its acquisition strategy. Breeze Networks is a managed service provider of cloud-based (SD-WAN) network connectivity and security solutions for enterprises
DNO Releases 2021 Corporate Social Responsibility Report15.8.2022 08:00:00 CEST | Press release
Oslo, 15 August 2022 – DNO ASA, the Norwegian oil and gas operator, today released its 2021 Corporate Social Responsibility Report. The report is attached as a downloadable file and is also available on the Company's website www.dno.no. – For further information, please contact: Media: email@example.com Investors: firstname.lastname@example.org – DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom, Netherlands and Yemen. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment 2021 CSR report
Sampo plc’s share buybacks 12/08/202215.8.2022 07:30:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 15/08/2022 at 08:30 am Sampo plc’s share buybacks 12/08/2022 On 12/08/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)14,42245.06AQEU29,72844.98CEUX9,01645.09TQEX76,83445.02XHELTOTAL130,00045.02 *rounded to two decimals On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based on the authorization granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 6,194,495 Sampo A shares representing 1.16 per cent of the total number of shares in Sampo plc. Details of ea
Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer15.8.2022 07:15:00 CEST | Press release
Phase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with stages II-IIIA and IIIB completely resected non-small cell lung cancer1 Findings will be presented at an upcoming medical meeting Novartis remains committed to pursuing new therapeutic options that can have a meaningful impact on the lives of people with lung cancer Basel, August 15, 2022 — Novartis announced today that the Phase III CANOPY-A study evaluating adjuvant treatment with canakinumab (ACZ885), an inhibitor of interleukin-1beta (IL-1β), in adult patients with stages II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) did not meet its primary endpoint of disease-free survival (DFS) versus placebo1. No unexpected safety signals were observed.1 Findings from the trial will be presented at an upcoming medical meeting. “We made an investment in the CANOPY program based on signals of reduced lung cancer incidence and mortality observed in the CANTOS s